1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: Big VC Money Backs Tech-Enabled Drug Discovery

 
• By Mandy Jackson

Private Company Edition: XtalPi raised $318.8m for its AI-based drug discovery platform and machine learning-enabled Flagship start-up Valo Health has brought in nearly $100m. XtalPi had one of three recent venture capital mega-rounds for China-based companies.

Finance Watch

Artificial intelligence and machine learning have moved from buzzwords to long-term business strategies in biopharmaceutical drug development with hundreds of millions of dollars invested in individual venture capital rounds in this space and an increasing number of collaborations with big pharma partners that are looking to speed up their drug discovery efforts.

Two recent VC financings highlight the anticipation that AI and machine learning are important new means for speeding new therapies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Venture Funding Plummets In Q2 As Mega-Rounds Falter

 
• By Mandy Jackson

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.

Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates

 
• By Mandy Jackson

Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

More from Business

Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates

 
• By Mandy Jackson

Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By Joseph Haas

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.